Immunoblot Analysis of Epigenetic Regulators

Immunoblot analysis was conducted as previously mentioned [19 (link)]. The primary antibodies used include anti-DNMT1 (1: 1000, ab87654, Abcam), anti-EZH2 (1: 1000; BD), anti-GAPDH (1: 1000, CST).

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Li N., Liu Y., Pang H., Lee D., Zhou Y, & Xiao Z. (2019). Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 25, 1590-1599.

Publication 2019

ab87654 anti-EZH2

Antibodies Dnmt1 Ezh2 Gapdh Immunoblot analysis

Corresponding Organization :

Other organizations : Harbin Medical University, Second Affiliated Hospital of Harbin Medical University

Top 5 similar protocols

Variable analysis

independent variables

None explicitly mentioned

dependent variables

Expression levels of DNMT1, EZH2, and GAPDH proteins

control variables

None explicitly mentioned

controls

Positive control: None mentioned
Negative control: None mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!